Company Profile
Relay Therapeutics Stock Price, News & Analysis
- Ticker:
- RLAY
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
19.75 USD (+0.30%)
Close
Last updated: August 6, 2026
3.42B USD
Market cap
Why the stock is moving
The latest monitored company update is “Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates.” The corresponding closing-price reaction is not yet available.
Company overview
Structure-Based Precision Medicine
Relay Therapeutics develops small-molecule medicines using a platform designed to model protein motion and identify druggable conformations. Its clinical portfolio focuses on genetically defined cancers and diseases driven by difficult-to-target proteins.
Zovegalisib in Breast Cancer
Zovegalisib is a mutant-selective PI3Kα inhibitor intended to preserve activity against oncogenic PIK3CA mutations while limiting inhibition of wild-type PI3Kα. It is being evaluated with fulvestrant in the Phase 3 ReDiscover-2 trial for previously treated HR-positive, HER2-negative advanced breast cancer.
Frontline Combination Strategy
Relay selected zovegalisib with atirmociclib and endocrine therapy as its preferred triplet for first-line endocrine-sensitive metastatic breast cancer. The approach combines selective PI3Kα and CDK4 inhibition while Relay retains global rights to zovegalisib.
Vascular Anomalies
Because activating PI3Kα mutations also drive many vascular anomalies, Relay is evaluating zovegalisib outside oncology. This program broadens the addressable population for the molecule and tests its mutant-selective profile in a genetic disease setting.
NRAS Program
RLY-8161 is an NRAS-selective molecule in Phase 1/2 development for NRAS-mutant solid tumors. The program adds a second clinically tested precision-oncology mechanism to Relay’s pipeline.
Future catalysts
Initial zovegalisib clinical data in vascular anomalies expected at the ISSVA meeting.
Initiation of a Phase 3 first-line breast-cancer trial of zovegalisib, atirmociclib and endocrine therapy expected in early 2027, subject to regulatory feedback.
Recent news
- 01
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
Source: Relay Therapeutics
- 02
- 03
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
Source: Relay Therapeutics
- 04
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
Source: Relay Therapeutics
- 05
Relay Therapeutics Announces Proposed Public Offering of Common Stock
Source: Relay Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Relay Therapeutics (RLAY)?
Relay Therapeutics (RLAY) most recently closed at 19.75 USD, a +0.30% move versus the previous session.
What is the market cap of Relay Therapeutics (RLAY)?
Relay Therapeutics currently has a market capitalization of 3.42B USD on BioPharmSignal.
What does Relay Therapeutics do?
Structure-Based Precision Medicine Relay Therapeutics develops small-molecule medicines using a platform designed to model protein motion and identify druggable conformations. Its clinical portfolio focuses on genetically defined cancers and diseases driven by difficult-to-target proteins. Zovegalisib in Breast Cancer Zovegalisib is a mutant-selective PI3Kα...
On which exchange is RLAY stock listed?
Relay Therapeutics (RLAY) is associated with NASDAQ, United States, Biopharma.
What is RLY-8161?
NRAS Program RLY-8161 is an NRAS-selective molecule in Phase 1/2 development for NRAS-mutant solid tumors.
Which conditions is Relay Therapeutics targeting with RLY-8161?
Relay Therapeutics is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does Relay Therapeutics describe recent progress with RLY-8161?
Initial zovegalisib clinical data in vascular anomalies expected at the ISSVA meeting. Initiation of a Phase 3 first-line breast-cancer trial of zovegalisib, atirmociclib and endocrine therapy expected in early 2027, subject to regulatory feedback.
What is atirmociclib?
Frontline Combination Strategy Relay selected zovegalisib with atirmociclib and endocrine therapy as its preferred triplet for first-line endocrine-sensitive metastatic breast cancer.